New Nylon O2Vent Optima Oral Device Launched in Australia
New Nylon O2Vent Optima Oral Device Launched in Australia
Brisbane, Jan 8, 2019 AEST (ABN Newswire) - Oventus Medical Ltd (ASX:OVN) is pleased to announce the launch of the O2Vent(R) Optima device in Australia, an important addition to the Company's sleep treatment platform.

Key points:

- New Oventus O2Vent(R) Optima oral device for the treatment of sleep apnoea launched in Australian market

- O2Vent(R) Optima is a compact, lightweight addition to the Oventus sleep treatment platform, with a reduced cost of goods in comparison with original titanium O2Vent(R)

- O2Vent(R) Optima incorporates Oventus' proprietary Airway Technology and is compatible with Oventus ExVent(TM) valve technology which will also be launched in 2019

- Clinical trials have shown that Oventus' proprietary airway alone or in combination with ExVent(TM) valve technology dramatically improves treatment outcomes for sufferers of obstructive sleep apnoea

The O2Vent(R) Optima is the newest product in the O2Vent(R) oral device range. It offers a new treatment alternative for the potentially fatal condition, obstructive sleep apnoea (OSA).

The O2Vent(R) Optima is a customised 3D printed nylon oral appliance that advances the jaw forward to open the airway and incorporates the Oventus proprietary Airway Technology to improve the effectiveness of oral appliance therapy. This device is lighter than the original O2Vent(R)and less complex to make. The combination of reduced material costs and lower manufacturing times bring down the cost of goods and will shorten timeframes on delivery of devices to patients.

Oventus Managing Director and CEO, Dr Chris Hart commented, "We are excited to be launching the O2Vent(R) Optima as the next generation O2Vent(R) product addition to our sleep treatment platform. This lightweight, durable device incorporating Oventus Airway Technology offers a more discreet and flexible alternative to those that cannot tolerate CPAP therapy".

The launch of O2Vent(R) Optima is the first of two new products coming to market in 2019. The second product being a valve that integrates with select O2Vent(R) devices to naturally increase airflow and airway stability. The valve is called the ExVent(TM) and has been clinically proven to dramatically increase the success rates of traditional mouthguard devices for sleep apnoea sufferers.

The ExVent(TM) was developed in collaboration with CSIRO and Neuroscience Research Australia (NeuRA) during the three year, $2.95 million Federally funded Cooperative Research Centres Project grant. ExVent(TM) is due to be released in Australia during Q1 calendar year 2019.

Following release of O2Vent(R) Optima and ExVent(TM) in Australia these products will be released in North American and European markets.

A CSIRO news release on Oventus' product innovations led to national media coverage on Friday 4 January, including on both Channel Seven and Nine News. The Seven News coverage can be seen on the Oventus news and media web page.

To view figures, please visit:

About Oventus Medical Ltd

Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2Vent(TM) is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

For more information on Oventus' Sleep Treatment Platform, please visit



Dr Chris Hart
Managing Director and CEO
M: +61-409-647-496

Jane Lowe
IR Department
M: +61-411-117-774 or

Related Companies

Oventus Medical Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 37) (Last 30 Days: 275) (Since Published: 3679)